"Tetrad Discovery is proud to announce our collaborative grant application under the Innovate UK Contracts for Innovation programme, focusing on advancing pre-clinical drug modelling through high-quality cell data.

Tetrad Discovery celebrates a decade of scientific leadership as Principal Scientist Rachel McCarthy marks 10 years of dedication to bio-analytical excellence, shaping our rigorous assay validation and internal R&D standards.

Tetrad Discovery scales our histology capabilities with the implementation of custom IHC panels, offering our partners higher specificity and superior sensitivity in tissue-based assay validation.

Tetrad Discovery prioritizes absolute timeline continuity. Throughout the challenges of the pandemic, our scientists maintained rigorous, uninterrupted laboratory operations to safeguard our clients' pre-clinical R&D pipelines

Tetrad Discovery strengthens our bio-analytical bench capacity, welcoming Virginija Page as Senior Associate Scientist to support our expanding portfolio of custom pre-clinical assay validation programs

Tetrad Discovery showcased our collaborative work on novel analyte validation at the inaugural European ELLA™ Simple Plex User Meeting, reinforcing our position as a leading UK CRO for automated immunoassay technology.

To address the challenges of traditional ELISA, Tetrad Discovery adopted the ELLA™ Simple Plex platform, delivering unparalleled reproducibility and high-sensitivity, automated bio-analysis for our drug development partners.

Tetrad Discovery continues to invest in the future of STEM, inspiring 2,000 local students at the Discovery Park Science Jamboree through interactive demonstrations of high-energy chemical principles and real-world analytical science.